Michael F Berger

80PUBLICATIONS
787CO-AUTHORS
Molecular targetsPredictive and prognostic markersEpigenetics (incl. genome methylation and epigenomics)Cancer therapy (excl. chemotherapy and radiation therapy)Cancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (80)

|Jun 26, 2026
Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer.

|Jun 24, 2026
The Genomic Landscape of MYC, MYCL, and MYCN Amplified Solid Tumors.

|Apr 22, 2026
Targeted Molecular Profiling of Circulating Cell-Free DNA in Patients With Gastroesophageal Adenocarcinoma.

|Mar 27, 2026
POLQ-driven repair scars shape the immunogenic landscape of homologous recombination-deficient pancreatic cancer.

Wungki Park, Shigeaki Umeda, Marc Hilmi

|Mar 26, 2026
Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial.

Wungki Park, Catherine A O'Connor, Joanne F Chou

|Mar 25, 2026
A Phase II Trial of Olaparib plus Pembrolizumab in Patients with Recurrent Copy Number-High/p53-Abnormal Endometrial Cancer.

Maria M Rubinstein, Jennifer Y Ge, Qin Zhou

Pageof 14

Frequent Collaborators

30 joint publications

David Solit

22 joint publications

Nikolaus Schultz

19 joint publications

Ahmet Zehir

18 joint publications

Marc Ladanyi